RxDoctor Payments Data

Joseph Castro, DO

Family Medicine · Midlothian, VANPI 1316252588

Payments from drug & device makers

$13,455in general payments, 2019–2025

Across 959 payments — averaging $14.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Novo Nordisk$1K
  • AstraZeneca$1K
  • Lilly USA, LLC$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$799
  • Boehringer Ingelheim$745
  • plus $5K from 47 others

What the payments were for

  • Food & beverage$13,19098%
  • Education$2642%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,455 in reported general payments places this provider in the 95th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$172,795
Medicare patients
519
Services billed
2,617

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide72$128,989
EliquisApixaban76$64,954
JardianceEmpagliflozin30$50,847
XareltoRivaroxaban30$43,170
Synjardy XrEmpagliflozin/Metformin Hcl20$32,140
Tresiba Flextouch U-200Insulin Degludec30$27,179
FarxigaDapagliflozin Propanediol22$24,045
LinzessLinaclotide33$21,517
MounjaroTirzepatide23$21,469
TrulicityDulaglutide11$12,540
Repatha SureclickEvolocumab12$12,092
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$11,844
MyrbetriqMirabegron15$7,576
Celecoxib138$6,640
Novolog FlexpenInsulin Aspart12$4,534

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,249$128,98972 claims
Boehringer IngelheimJardiance, Synjardy Xr$745$82,98750 claims
PfizerEliquis, Paxlovid$682$66,38399 claims
Johnson & JohnsonXarelto$227$43,17030 claims
Lilly USA, LLCMounjaro, Trulicity$1,113$34,00934 claims
AstraZenecaFarxiga$1,123$24,04522 claims
AbbVieLinzess, Synthroid$3,257$22,74762 claims
GSKTrelegy Ellipta$153$11,84411 claims
Astellas Pharma US IncMyrbetriq$101$7,57615 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$32$2,515271 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Midlothian

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →